Company intelligence / Profile preview

Alligator Holdings

Lund, Skåne län, Sweden

Ownership: Private
Employees: ~62
Development stage: Other

Overview

Mitazalimab, the lead candidate targeting CD40, has shown unprecedented survival data at 24-month follow-up in first-line metastatic pancreatic cancer patients in the Phase 2 OPTIMIZE‑1 trial and is being prepared for Phase 3 development. The company also has several partnered and outlicensed assets advancing through clinical and preclinical stages.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Partnerships

Aptevo Therapeutics Inc. (ALG.APV‑527 co-development)Orion Corporation (RUBY® bispecific platform collaboration)Shanghai Henlius Biotech Inc. (“AC101/HLX22” out-license)Biotheus Inc. (“undisclosed” program out-license)

Beyond the preview

Go deeper on Alligator Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alligator Holdings.

Explore the full profile